ALPHAEON Announces Results from Two Phase III Trials of DWP-450 Botulinum Toxin Type A

ALPHAEON Corporation today announced positive data from two Phase III clinical trials of its DWP-450 botulinum toxin type A neuromodulator at the American Society of Aesthetic Plastic Surgery meeting inLas Vegas, NV.
According to the news:

DWP-450 was studied in subjects with glabellar lines, which are also known as “frown lines” between the eyebrows. In the two phase III randomized, multi-center, placebo-controlled, double blind trials (EV001 and EV002), DWP-450 successfully achieved the studies’ primary efficacy endpoint. The composite endpoint required both the investigator and the study subject to independently agree that there had been at least a 2-point improvement 30 days after the treatment when compared to baseline (pre-treatment). The responder rate was 67.5% in the EV001 study and 70.4% in the EV002 study and both studies were statistically superior to their respective placebo control groups.

Chris Marmo, President of Beauty for ALPHAEON, said:

The results of our phase III clinical trials marks a significant milestone for ALPHAEON. It’s a great advancement in the regulatory process and we look forward to leveraging our unique and innovative social commerce platform to offer this product to board certified specialty physicians.

Click here to view the full press release.